

(etrasimod)^{2mg}

Program Enrollment Form

For assistance, call 1-800-350-3080, M-F 8AM-8PM EST Fax COMPLETED pages 1-3 with a cover sheet to 1-646-862-9655.

FOR PATIENTS – Complete the following sections, then read, sign, and date (where applicable) the required authorization consents on pages 2 and 3. Missing information or consents may cause delays in filling your prescription and signing you up for the VelsipityForMe Program.

1		ATION (*=required field) Co					
Firs	rst Name*MI		Last Name*	Last Name*		DOB (mm/dd/yyyy)*	
Sex	* □Male □Female (S	ex describes one's biology a	t birth)		o , , t	710+	
Prin	nary Address" nary Phone*	N	City	/"	State" Permission to le	ZIP" Pave a Voicemail*: DV DN	
Bes	t Time to Contact: 🔲	AM PM Preferred Langu	ige (if not English): Pre		State*ZIP* Permission to leave a Voicemail*:YN Ferred Communication*:PhoneEmail		
Ema	ail (Required to access V	'elsipityForMe Patient Portal)* : Name					
Pati							
2		RMATION (* = required fiel)	
□S	ee attached copy of m	y insurance card(s), front and	,				
		Primary Prescription	nsurance Sec	ondary Prescription li	nsurance Prim	ary Medical Insurance	
	urance Name*						
	urance Phone* icy ID#*						
	bup #*						
	icyholder Name*						
BIN	-						
PCI	N#						
FC	RHEALTHCARE	PROFESSIONALS - Co	mplete the followin	a sections and sign t	his page.		
		o been sent to a Specialty Pl				e Number	
		ORMATION (*= required fie			01111101		
				Last*			
NPI	#*	State	icense #*	Last Pr	actice Name*		
Add	lress*		City	/*	State*	ZIP*	
Offi	ice Contact Name* _		Off	ice Contact Phone* _		Ext	
Ema	ail		Office Fax*		Best	Time to Contact: □AM □PM nguage □English □Spanish	
		SMENTS ⁺ ([*] = required field)		sured eligible patients	s. See Terms and Conditio	ns on pg. 4	
		sistance Request on Behalf	of the Patient:		Starting therapy:*		
Assessment assistance requested: Conduct assessments at patient's home (check al			that apply)		Patient CAN proceed with treatment.		
\Box ECG \Box Ophthalmic Exam Blood tests: \Box CB							
Schedule assessments in a provider's office (chec			k all that apply)		□ Patient is NOT yet cleared for therapy.		
				to facilitate scheduling only.			
		sment that was already co ation of an ECG. Fax ECG t					
		lable for an ECG previously co		st 6 months.			
5 PRESCRIPTION INFORMATION (*= required field) Interim Care Rx is for commercially insured patients, and is only filled through Sonexus Health Pharmacy Services.							
	By requesting this, you certi	fy you understand the terms and conc	litions on page 4. See full Int	erim Care Rx and Voucher Rx T	Ferms and Conditions on page 4		
	Dosage &	Quantity	Rx Refills*	Voucher Rx [‡]	Interim Care Rx [†] Up to 2 years	Interim Care Rx Refills Up to 11	
	VELSIPITY, 2 mg, PO	, Once-daily, 30 tablets*				,	
		irmation Form is required prio	to dispensing medica	ation if ECG and/or bloo	d testing support is requ	ested or if assessments are	
	g completed independ	ently. If ves. please list medicatio	a(c) and accordiated r	opertion(s)		known drug allergies (NKDA)	
	3 • 3 • • - • •	7	(-,			KIIOWITUTUY allergies (INDA)	
6		SIS (REQUIRED) Complete the	,	Ũ			
	NOT ATTACH ANY CLI erative Colitis K51.	NICAL OR OFFICE NOTES	A S THIS MAY DELAY Other	PROCESSING THE FO	DRM		
		OVIDER CERTIFICATION		entified in this form. If	irther certify that I have	made an independent iudament	
that	the above therapy is m	edically necessary, and that t	he information provide	ed in this form is accura	te to the best of my know	made an independent judgment vledge. I authorize Pfizer, and its	
attili	, , , ,	atives, and service providers	to act on my behalf fo	r the purposes of transr	nitting this prescription t	o the appropriate pharmacy.	
Dre	X	NO STAMPS		f Haalthaana Drait		Doto*	
				of Healthcare Provid	· · · ·	Date* at you have received patient consent	
for EM	Sonexus Health Pharmacy R/EHR systems and is locate	Services and VelsipityForMe to cor ed at 2730 S. Edmonds Lane, Suite	itact your patient and prov	ide them services. Sonexus	s Health Pharmacy Services is in New York state, please use	s categorized as a retail pharmacy in a New York state prescription form.	
†Term ‡The	ns and conditions apply. See	page 4 for terms and conditions. ited trial supply to evaluate the safe	tv and efficacy of the med	ication.	GLOBAL: https://www.pfiz	er.com/privacy	

FOR PATIENTS

8 PATIENT AUTHORIZATION TO SHARE HEALTH INFORMATION (*= required field)

By signing and dating this form, I give my permission for my physicians, pharmacies, laboratories, and other healthcare providers ("Healthcare Providers") and my health insurers to share my health information with Pfizer Inc., the Pfizer Patient Assistance Foundation™, Pfizer affiliates, and its vendors (collectively, "Pfizer"). I understand that my health information includes information relating to my medical condition, treatment, and insurance coverage, as well as identifying information about me (including, for example, my name, address, and date of birth). My health information will be shared with Pfizer so that Pfizer may provide me with various support and information to help me access a Pfizer medicine, which may include the following, depending on your program (collectively, "Patient Support Activities"):

• Providing benefits investigations/verification and reimbursement support, including:

'elsipitv

etrasimod) ^{2mg}

- Assisting with identification of my insurer's prior authorization requirements
- Assisting with identification of my insurer's requirements for appealing a denied claim
- · Determining my eligibility for and helping me access co-pay support or free drug programs
- Communicating with my Healthcare Providers about a Pfizer medicine and Patient Support Activities
- · Providing me with financial assistance resources and information if I'm eligible
- Providing assistance with coordinating baseline assessment/prescreening tests if I've requested and am eligible
- Providing me with disease management and other educational materials, as well as information about Pfizer's products, services, and programs, and may include sending me surveys about my experience with Pfizer's products, services, and programs
- Pfizer also may use my health information for quality assurance purposes and to evaluate and improve their operations and services

I understand that I do not have to sign this form and choosing not to sign will not affect my ability to receive treatment from my Healthcare Providers or payment from my health insurer. However, if I do not sign and date this form, VelsipityForMe may not be able to provide me with assistance. I understand that once my health information is shared, it may no longer be protected by federal privacy law. I consent to Pfizer using my health information for the purposes described in this form or as required or permitted by law. Select pharmacies may receive remuneration from Pfizer in exchange for my health information and/or for any Patient Support Activities provided to me. I understand that this form will remain in effect for 4 years from the date of my signature unless state law requires a shorter period, or I provide written notice that I would like to withdraw my approval to share my health information sooner. If I would like to withdraw my approval, I may contact my physician or I may contact VelsipityForMe at 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067, Monday–Friday, 8AM–8PM ET, M–F or at 1-800-350-3080. This withdrawal will not affect the use or sharing of my health information that took place before I withdrew my approval. I understand I will receive a copy of this form.

	Χ	

Patient Signature^{*} (Patient or patient representative must be 18 or older)[†]

Date*

X

Patient representative name (please print)[‡]

If signed by patient representative, please indicate below the authority to act on behalf of patient[§]:

□ Court Appointed □ Guardian □ Power of Attorney, including authority to make healthcare decisions □ Other

[†]Patients who are 18 years or older must sign unless incapacitated; otherwise, a representative with one of the legal authorities noted below can sign on their behalf. [‡]NOT required if patient signs.

[§]Required if patient representative signs.



FOR PATIENTS

9 PATIENT PRIVACY NOTICE AND CONSENT TO PROCESS HEALTH INFORMATION (*= required field)

(etrasimod) ^{2mg}

By checking the box below, you understand that Pfizer, Inc., the Pfizer Patient Assistance Foundation, Pfizer's affiliates, and its vendors (collectively, "Pfizer") will use the health information you and your healthcare providers provide us to provide you with the Patient Support Activities. You have the right to withdraw these permissions at any time and can do so by contacting VelsipityForMe at 1-800-350-3080. You can find more information about how Pfizer Inc. handles your personal information in our Privacy Policy at pfizer.com/privacy.

I understand that I have the right to withdraw my consent by calling 1-800-350-3080, and that if I withdraw my consent it will be effective for any future disclosures but will not affect disclosures already made.

🗆 * I understand and consent to the terms of the Privacy Notice and Consent to Process Health Information

10 PATIENT CONSENT TO RECEIVE CALLS AND TEXTS (*= required field)

By providing my mobile number and checking the box below, I or my caregiver agree to receive calls and texts from Pfizer or parties acting on its behalf, to determine my eligibility and provide benefits verification, prior authorization/appeals assistance, financial assistance resources, refill reminders from VelsipityForMe, information and other Patient Support Activities (such as copay support or free drug programs) and for other non-marketing purposes (such as enrollment status and shipping updates) at the telephone number(s) I or my caregiver provide.

Please enter the mobile number you would like to enroll for texting (____) ____-

\blacktriangleright \Box^* I or my caregiver agree to receive calls and texts from Pfizer or parties acting on its behalf as stated.

I understand that I (and, if applicable, my caregiver) can opt out of these communications at any time by contacting VelsipityForMe at 1-800-350-3080. I understand that my consent is not required and is not a condition of purchasing any goods or services from Pfizer. Message and data rates may apply. Complete terms can be found at https://velsipityforme.pfizer.com/sms-terms and Pfizer's privacy policy at www.pfizer.com/privacy. Text STOP to opt out. https://velsipityforme.pfizer.com/sms-terms

By providing my signature, I confirm that I completed this form, including any authorizations/consents/check-boxes.

X

Patient Signature* (Patient or patient representative must be 18 or older)⁺

Date



Patient representative name (please print)[‡]

[†]Patients who are 18 years or older must sign unless incapacitated; otherwise, a representative with one of the legal authorities noted below can sign on their behalf. [‡]NOT required if patient signs.



INTERIM CARE RX PROGRAM TERMS & CONDITIONS

Interim Care is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for VELSIPITY™ (etrasimod). The Interim Care Program is applicable to all VELSIPITY™ formulations. No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party paver. Not available to patients covered under Medicaid. Medicaid or other federal or state healthcare programs, including any state prescription drug assistance programs and the Government Health Insurance Plan or for residents of Massachusetts or Michigan. For residents of Minnesota or Rhode Island, available for up to six months. For all other eligible patients, this program is available for a period of up to two years (lifetime maximum) or until they receive insurance coverage approval, whichever occurs earlier. Available in 30-day supply. Refills are subject to limitations. Continued eligibility for the program requires, 1. submission of first appeal within 60 days of enrollment (or within the required payer timeline, if sooner) in the Interim Care Program and submission of the second appeal, if allowed by the payer, within 60 days of the date of the first appeal denial (or within the required payer timeline, if sooner), 2. satisfying all payer appeal requirements and 3. patients schedule their initial prescription dispense within 60 days of enrollment. If at any time during the patient's Interim Care Program enrollment there is a payer coverage change relating to the applicable product, Pfizer may conduct a new benefits investigation, and, if allowed by the payer, submission of a new Prior Authorization request and an appeal, if denied, must be submitted within 60 days (or within the required payer timeline, if sooner) of either, 1. the date of completion of the benefits investigation, provided by the VelsipityForMe Program to the patient's authorized healthcare provider, or 2. the date a new submission is allowed by the payer, for continued eligibility in the program, whichever is later. If there is no payer coverage change, at 12 months of Interim Care Program enrollment, an updated prescription and benefits investigation is required to confirm continued eligibility. Interim Care offer does not require, nor will be made contingent on, purchase requirements of any kind. Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification. Interim Care can only be dispensed by the exclusive pharmacy and only after a benefits investigation has been completed and a delay occurs in the Prior Authorization process, or an appeal is required. All payer appeal timelines must be met for continued assistance. Offer good only in the U.S. and Puerto Rico. Prescription must be provided by a healthcare provider licensed in the U.S. or Puerto Rico. Additional eligibility criteria may apply. Contact VelsipityForMe at 1-800-350-3080 for details.

elsiditv

VOUCHER TERMS AND CONDITIONS

- · You will receive a one-time 30-day supply of VELSIPITY.
- · Only new patients may use this voucher and each patient is limited to one voucher. By redeeming this voucher, you certify that you are not currently using VELSIPITY.
- This voucher may not be transferred, sold, purchased, traded, or counterfeited.
- · An original voucher and a valid prescription must be presented to the pharmacy.
- The voucher will be accepted only at participating pharmacies
- You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third party payor, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
- This voucher is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third party insurance.
- This voucher is not valid where prohibited by law.
- . This voucher cannot be combined with any other external savings, free trial or similar offer for the specified prescription. This voucher should not be combined with samples for the specified prescription.
- This free trial voucher is not health insurance.
- This free trial voucher may not be used to address delays or gaps in health insurance coverage for the specified prescription. Offer good only in the U.S. and Puerto Rico.
- · No purchase is necessary.
- · Patients have no obligation to continue to use VELSIPITY. · Pfizer reserves the right to rescind, revoke or amend this offer without notice.
- This voucher expires 12/31/2025.
- You must be 18 years of age or older to redeem this voucher.

VELSIPITY AT-HOME BASELINE ASSESSMENT/PRESCREENING TESTS AND IN OFFICE SCHEDULING PROGRAM TERMS AND CONDITIONS

By agreeing to participate in the VELSIPITY At-Home Baseline Assessment/Prescreening Tests Program or the In Office Scheduling Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

- Patients are not eligible for the VELSIPITY At-Home Baseline Assessment/ Prescreening Tests Program and/or In Office Scheduling Program if they are enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or if they reside int Michigan, Minnesota, or Rhode Island.
- The VELSIPITY At-Home Baseline Assessment/Prescreening Tests Program and In Office Scheduling Program are valid only for patients with commercial (private) insurance.
- The VELSIPITY At-Home Baseline Assessment/Prescreening Tests Program include initial blood test, ECG screening, and eye exam.
- The In Office Scheduling Program includes scheduling for skin testing and an eye exam only based upon certain identified demographic criteria.
- The VELSIPITY At-Home Baseline Assessment/Prescreening Tests Program and In Office Scheduling Program are not health insurance.
- Patients must be enrolled in the VelsipityForMe program to participate in the VELSIPITY At-Home Baseline Assessment/Prescreening Tests Program and/or the In Office Scheduling Program.

VELSIPITY ECG INTERPRETATION TERMS AND CONDITIONS

· Offers are only available to patients who have been diagnosed with an FDA-approved indication for VELSIPITY (etrasimod). Offers only good in the U.S. and Puerto Rico.

- · No other purchase is necessary.
- The programs are not valid where prohibited by law.
- · Patient must be 18 years of age or older.
- · If requesting either an ECG and or initial blood test through the At-Home Baseline Assessment/Prescreening Tests Program, other support services offered through VelsipityForMe cannot begin until a signed Baseline Assessment Confirmation form is received by VelsipityForMe.
- · Pfizer reserves the right to rescind, revoke, or amend the programs without notice. · If you have questions or are in need of additional support, call 800-350-3080,
- visit www.VELSIPITY.com, or mail to VelsipityForMe at 2730 S. Edmonds Lane, Suite 300, Lewisville TX 75067. 🧮 GLOBAL: https://www.velsipity.com/

By agreeing to participate in the VELSIPITY ECG Interpretation Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

- Patients are not eligible for the VELSIPITY ECG Interpretation Program if they are enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or if they reside in Michigan, Minnesota, or Rhode Island.
- · The VELSIPITY ECG Interpretation Program is valid only for patients with commercial (private) insurance.
- The VELSIPITY ECG Interpretation Program is only available to patients if an ECG has been previously conducted within 6 months of the request for service.
- The VELSIPITY ECG Interpretation Program is not health insurance.
- · Patients must be enrolled in the VelsipityForMe program to participate in the VELSIPITY ECG Interpretation Program.
- Offer is only available to patients who have been diagnosed with an FDA-approved indication for VELSIPITY (etrasimod).

- Offer only good in the U.S. and Puerto Rico.
- No other purchase is necessary.
- · The program is not valid where prohibited by law.
- · Patient must be 18 years of age or older.
- Other patient support services offered through VelsipityForMe cannot begin until a signed Baseline Assessment Confirmation form is received by VelsipityForMe.
- · Pfizer reserves the right to rescind, revoke, or amend the program without notice.
- If you have questions or are in need of additional support, call 800-350-3080, visit www.VELSIPITY.com, or mail to VelsipityForMe at 2730 S. Edmonds Lane, Suite 300, Lewisville TX 75067.

